CERS1 and pancreatic ductal adenocarcinoma: Ceramide synthase 1 (CerS1), however pancreatic ductal adenocarcinoma (PDAC) remains as one of the most aggressive malignancies with a median 5 year-survival rate of 12% (Puckett and Garfield, 2022).